Holen Sie sich die Stockscreener-App
1.43
0.70%
0.01
Handel nachbörslich:
1.46
0.03
+2.10%
Schlusskurs vom Vortag:
$1.42
Offen:
$1.43
24-Stunden-Volumen:
233.13K
Relative Volume:
0.76
Marktkapitalisierung:
$20.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.81M
KGV:
-0.4955
EPS:
-2.8859
Netto-Cashflow:
$-17.01M
1W Leistung:
-10.06%
1M Leistung:
-55.31%
6M Leistung:
-80.96%
1J Leistung:
-43.03%
1-Tages-Spanne:
$1.39
$1.545
1-Wochen-Bereich:
$1.37
$1.6398
52-Wochen-Spanne:
$0.89
$13.48
Cel-Sci Corp. Stock (CVM) Company Profile
Firmenname
Cel-Sci Corp.
Sektor
Branche
Telefon
703-506-9460
Adresse
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
1.43 | 20.58M | 0 | -23.81M | -17.01M | -2.8859 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-02 | Eingeleitet | Dawson James | Buy |
Cel-Sci Corp. Aktie (CVM) Neueste Nachrichten
CVM: CEL-SCI Advances Multikine Toward Regulatory Approval - GuruFocus
[RW] CEL SCI CORP SEC Filing - Stock Titan
Cel Sci CEO Geert Kersten’s trust buys $360,000 in common stock By Investing.com - Investing.com South Africa
Cel Sci CEO Geert Kersten’s trust buys $360,000 in common stock - Investing.com Australia
Cel Sci Insider Bought Shares Worth $360,000, According to a Recent SEC Filing - marketscreener.com
CEL-SCI (NYSE: CVM) trust buys 300K restricted shares at $1.20 - Stock Titan
CEL-SCI adds Saudi partner, U.S. trial for head and neck cancer drug - Stock Titan
Cel-Sci: Fiscal Q2 Earnings Snapshot - cbs19news.com
CEL SCI CORP 1H 2026: Net loss $(10.94M), Diluted EPS $(1.35) — 10-Q Summary - TradingView
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 - marketscreener.com
CEL-SCI (NYSE: CVM) reports $10.9M loss and just $1.9M in cash - Stock Titan
CEL-SCI Partners with Amarox for Multikine Cancer Immunotherapy Commercialization in Saudi Arabia and GCC Region 12 - Minichart
CEL-SCI (NYSE: CVM) partners with Amarox on Multikine in Saudi Arabia - Stock Titan
CEO Geert Kersten Increases Stake in CEL-SCI Corp with Recent Sh - GuruFocus
Cel-Sci Corporation Common Stock (NY: CVM - FinancialContent
CEO Geert Kersten Increases Stake in CEL-SCI Corp with Recent Share Purchase - GuruFocus
Cel Sci CEO Geert Kersten acquires $119,000 in common stock - Investing.com India
Cel Sci CEO Geert Kersten acquires $119,000 in common stock By Investing.com - Investing.com South Africa
CEL SCI (CVM) CEO Geert Kersten purchases 100,000 restricted shares - Stock Titan
CEL-SCI Raises $7.2 Million in Stock Offering; Placement Agreement With ThinkEquity - TradingView
CEL-SCI (NYSE: CVM) prices $7.2M best-efforts stock offering - Stock Titan
CEL-SCI closes $7.2M public offering at $1.20 per share - Investing.com
Cancer immunotherapy firm CEL-SCI raises $7.2M for Multikine - Stock Titan
CEL‑SCI (NYSE American: CVM) to sell 6.0M shares; raises ~$6.5M net - Stock Titan
Cel-Sci Corp files for offering of 6 million shares of common stockSEC filing - marketscreener.com
Cel-Sci Corp Files For Offering Of 6 Million Shares Of Common Stock- SEC Filing - TradingView
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session. - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
[EFFECT] CEL SCI CORP SEC Filing - Stock Titan
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Did CEL-SCI Stock Plunge After Its Latest Offering - Kavout
CVM: ThinkEquity Completes Sole Management of Offering - GuruFocus
CEL-SCI prices $7.2M public offering at $1.20 per share By Investing.com - Investing.com South Africa
CEL-SCI prices $7.2M public offering at $1.20 per share - Investing.com
Cancer immunotherapy firm CEL-SCI seeks $7.2M to develop Multikine - Stock Titan
CEL-SCI Corporation Announces Pricing of Public Offering - Yahoo Finance
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Strategic Partnership for CEL-SCI (CVM) Enhances Multikine's Mar - GuruFocus
CEL-SCI partners with Amarox for Multikine in Saudi Arabia By Investing.com - Investing.com South Africa
CEL-SCI partners with Amarox for Multikine in Saudi Arabia - Investing.com India
Saudi bid to fast-track cancer immunotherapy with new CEL-SCI deal - Stock Titan
Cel-Sci CVM shares surge 10% after Q4 earnings beat; quarterly loss narrower than analysts expected.Balance Sheet - newser.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
EDGAR Filing Documents for 0001654954-26-004295 - SEC.gov
CEL-SCI (NYSE: CVM) moves to fund Multikine with $13.7M best efforts stock sale - Stock Titan
CVM - Finviz
New LowStock ScreenerSnapshot - Finviz
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Eom Pharmaceutical Holdings Inc (IMUC) - MSN
Finanzdaten der Cel-Sci Corp.-Aktie (CVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):